Development

Tanakan for children: instructions for use

The active ingredient of the over-the-counter drug "Tanakan" is an extract of Ginkgo biloba leaves. On the basis of this popular plant today, many drugs are produced, it is often included in dietary supplements, however, in the medical environment, the attitude towards it is still ambiguous. Critics argue that its positive effects are exaggerated.

Feasibility of use in children

Instructions for use of the drug "Tanakan" informs about its undesirable use in childhood (up to 18 years). But it so happens that the manufacturer of the drug writes one thing, but in fact the drug is often prescribed even to infants. This is just such a case.

Most doctors refer to the positive experience of therapy with this herbal remedy, but Dr. Komarovsky has a different opinion on this matter, since the child's body is not identical to the adult.

Before treatment with "Tanakan", a thorough comprehensive examination will not interfere in order to take into account the individual characteristics of the organism.

Affiliation to pharmacological groups

The drug is a plant-derived angioprotector used as a microcirculation corrector. The action consists in antispasmodic activity, a positive effect on blood vessels, improving microcirculation and rheological properties of blood, increasing capillary resistance, reducing tissue edema, restoring metabolism in the walls of blood vessels.

It belongs to the correctors of cerebral circulation disorders, which have a beneficial effect on the blood supply to the brain, microcirculation, oxygen processes. It normalizes the metabolism of brain tissue, is able to prevent the development of ischemic brain damage, but with some side effects. It has a positive effect on the metabolism of the ischemic brain due to its antioxidant and antihypoxic effect.

Composition and dosage form

The preparation contains dry extract of ginkgo biloba and excipients. It is available in several forms: a solution (which is often mistaken for a syrup or drops) for ingestion, a dirty orange color with a specific odor and biconvex round tablets, covered with a brick-colored shell with a light brown content. All analogues of this drug have their own characteristics, therefore, they are not recommended as an alternative.

Pharmachologic effect

The main pharmacological action of the drug is considered to improve cerebral circulation. The therapeutic effect is due to its effect on metabolic processes inside cells, some characteristics of blood, vasomotor vascular.

The drug improves oxygen supply to the brain, restores arterial and venous tone, microcirculation, metabolism, blood flow, reduces the tendency of erythrocytes to aggregate, inhibits platelet activity, acts as an antihypoxant, affects the processes associated with the work of certain neurotransmitters (norepinephrine, acetylcholine, dopamine, serotonin). Due to its direct and indirect effect on brain processes, it is effective in treating:

  • intellectual and mnestic pathologies;
  • difficulty concentrating and distracted;
  • mental infantilism and cognitive disorders;
  • various kinds of violations of intelligence and thinking;
  • memory impairment and decreased mental performance;
  • decrease in mental activity, mental function.

May act as a prophylactic agent for cerebrovascular disorders, reducing the risk of disability and death from stroke.

Method of administration and dosage

Tanakan should be taken orally after meals with plenty of water. The dosage for children under 7 years old is different from that given to adolescents. Single dose for adults: a tablet or milliliter of solution (pick up with a pipette and dissolve in half a glass of water). In both cases, it is taken 3 times a day.

The course of treatment is from three to six months (minimum), a persistent improvement in the condition appears after a month of admission. The bioavailability of the drug is almost 90% when taken orally. The maximum concentration in the blood is observed an hour or two after ingestion, it is excreted mainly by the kidneys.

Indications

The indications for the appointment are diseases, mainly associated with pathologies of the vascular system:

  • Sensorineural and cognitive deficits of various origins (when the pathogenesis of this kind of disorder is caused by a metabolic failure, the correction of which leads to the normalization of mental functions). An example of such reversible cognitive impairments is dysmetabolic encephalopathy, pathology of higher cerebral functions with dropsy or brain tumor, anxiety-depressive pathologies, dementia.
  • Intermittent claudicationcaused by chronic arteriopathy of the lower extremities. Due to systematic vasospasm and damage to nerve endings, an ischemic process occurs. Dystrophic neurovascular pathology leads to pain during walking, a feeling of tension, heaviness, paresthesia.
  • Visual impairment of vascular origin, a decrease in its severity (the main causes of damage to the vessels of the visual zone are infectious (most often ENT diseases, atherosclerosis, hypertension, hypotension, arteritis, periarthritis).
  • Hearing pathology, tinnitus, predominantly of a vascular nature (infections, including ENT organs, atherosclerotic, dyscirculatory, dystonic changes in the vessels with atherosclerosis, hypertension, NCD).

  • Diseases associated with the vestibular apparatus, dizziness, vertigo, problems with stability, ischemic impairment of hearing and balance (vestibular problems caused by vascular diseases of the brain are in the first place among the rest).
  • The drug is prescribed for children with mild cognitive impairment (characterized by a decrease in memory, a pronounced feeling of fatigue during mental activity, difficult learning, the inability to concentrate on one process for a long time, when learning new things seems difficult, even when in fact it is successful).
  • Raynaud's disease and syndrome (the occurrence is associated with a disorder of the regulatory function of the vessels of the sympathetic nerves, which causes their narrowing and an increase in resistance to blood flow, which causes local tissue ischemia).

Effective "Tanakan" and intellectual-mnestic pathologies (impaired memory, intellect, emotional-volitional sphere, difficulty in acquiring new knowledge and skills, automation of actions, poor stereotyped speech, lack of control of emotions, irascibility). The positive experience of using "Tanakan" for such violations contributed to its popularization.

The need to prescribe the drug to a premature baby is carefully weighed, but if the baby, for example, is 3 years old, then the practice of prescribing is widespread. According to neurologists, in infancy and childhood, the drug can quickly reduce intracranial pressure, stabilize the psycho-emotional state, remove the RRR, and normalize the work of the musculoskeletal system.

Contraindications and side effects

The drug should not be taken with high sensitivity to its components, children and minors with stomach diseases, impaired absorption of lactose, myocardial infarction, low blood clotting, pregnancy, breastfeeding.

Possible side effects of the drug include headache, dizziness, nausea, dermatological and allergic symptoms. In rare cases, dyspeptic disorders, indigestion, decreased blood clotting, hemorrhages (with prolonged use) may occur.

If any discomfort occurs, the drug is canceled.

Feedback from parents

This drug has not been shown to be toxic in clinical trials. Parents' reviews of this tool contain different impressions. Some argue that they did not notice the changes, others are sure that the drug had a positive effect, and still others blame it for changing the child's well-being and behavior not for the better. But, perhaps, "Tanakan" has nothing to do with it, and the reason lies in any individual characteristics or in the presence of other diseases.

It is impossible to prescribe this medication for children on your own, only a specialist can assess the need for its use.

See the doctor's comments on the drug in the following video.

Watch the video: Ginkgo biloba extract EGb 761 for cognitive impairment: clinical data (July 2024).